menu
    • menu
    [{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Plex Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Atavistik Bio \/ Plex Research","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ Plex Research"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ATV-1601","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Atavistik Bio \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Atavistik Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Atavistik Bio

    Menu

    Atavistik Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATV-1601

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atavistik Bio Nominates ATV-1601, A Precision Oncology Candidate

                            Details : ATV-1601 is an allosteric small molecule inhibitor for AKT1 E17K. It is currently being evaluated for the treatment of AKT1 E17K mutated cancers, such as breast, Prostate, and endometrial cancer.

                            Brand Name : ATV-1601

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 15, 2024

                            Lead Product(s) : ATV-1601

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : The Column Group

                            Deal Size : $40.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics

                            Details : The net proceeds will enable Atavistik to advance its lead precision allosteric small molecule therapeutic in oncology into the clinic and to advance its earlier stage pipeline.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 19, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : The Column Group

                            Deal Size : $40.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Plex Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Pl...

                            Details : Atavistik Bio will enhance its proprietary Interactome map with Plex Research’s cloud-based AI-powered drug discovery search engine of large and disparate data sources to reveal hidden connections between related metabolites and ligands.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 10, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Plex Research

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Atavistik Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : The Column Group

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic D...

                            Details : The financing will support development of Atavastik’s drug discovery platform, and future identification of select drug candidates based on knowledge of disease relevant pathways that have evolved over millions of years by nature to be allosterically r...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 24, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : The Column Group

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth